Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3947/ic.2020.52.2.281 http://scihub22266oqcxt.onion/10.3947/ic.2020.52.2.281 32342676!7335642!32342676     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32342676.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Infect+Chemother 2020 ; 52 (2): 281-304 Nephropedia Template TP {{tp|p=32342676|t=2020. Interim Guidelines on Antiviral Therapy for COVID-19 |pdf=|usr=}}{{32342676}} gab.com Text Interim Guidelines on Antiviral Therapy for COVID-19 JO: Infect Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32342676 #FOAvip Since the first case was reported in Wuhan, Hubei Province, China on December 12, 2019, Coronavirus disease 2019 (COVID-19) has spread widely to other countries since January 2020. As of April 16, 2020, 10635 confirmed cases have been reported, with 230 deaths in Korea. COVID-19 patients may be asymptomatic or show various clinical manifestations, including acute symptoms such as fever, fatigue, sore throat; pneumonia presenting as acute respiratory distress syndrome; and multiple organ failure. As COVID-19 has such varied clinical manifestations and case fatality rates, no standard antiviral therapy regimen has been established other than supportive therapy. In the present guideline, we aim to introduce potentially helpful antiviral and other drug therapies based on in vivo and in vitro research and clinical experiences from many countries. Twit Text FOAVip Interim Guidelines on Antiviral Therapy for COVID-19 ????Infect Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32342676 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32342676 #FOAvip English Wikipedia <ref>{{Cite pmid|32342676}}</ref> Interim Guidelines on Antiviral Therapy for COVID-19 #MMPMID32342676 Kim SB; Huh K; Heo JY; Joo EJ; Kim YJ; Choi WS; Kim YJ; Seo YB; Yoon YK; Ku NS; Jeong SJ; Kim SH; Peck KR; Yeom JS Infect Chemother 2020[Jun]; 52 (2): 281-304 PMID32342676show ga Since the first case was reported in Wuhan, Hubei Province, China on December 12, 2019, Coronavirus disease 2019 (COVID-19) has spread widely to other countries since January 2020. As of April 16, 2020, 10635 confirmed cases have been reported, with 230 deaths in Korea. COVID-19 patients may be asymptomatic or show various clinical manifestations, including acute symptoms such as fever, fatigue, sore throat; pneumonia presenting as acute respiratory distress syndrome; and multiple organ failure. As COVID-19 has such varied clinical manifestations and case fatality rates, no standard antiviral therapy regimen has been established other than supportive therapy. In the present guideline, we aim to introduce potentially helpful antiviral and other drug therapies based on in vivo and in vitro research and clinical experiences from many countries. äInterim Guidelines on Antiviral Therapy for COVID-19 (epmc).pdf DeepDyve Pubget Overpricing